Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been clinically diagnosed with hepatocellular carcinoma (a type of liver cancer).
- People aged between 18 and 75 years.
- People whose largest tumor measures at least 10 cm, and whose total tumor size is at least 15 cm.
- People with intermediate to advanced large liver cancer, including cases where the cancer has spread into certain nearby blood vessels (portal vein, types I or II) or has a limited number of spread sites (5 or fewer).
- People whose liver function falls into Child-Pugh class A or B, which are measures of how well the liver is working (confirm with trial site).
- People who are reasonably active and able to carry out daily activities, rated 0 to 2 on a standard health performance scale.
- People whose blood test results meet specific levels for hemoglobin, bilirubin, albumin, liver enzymes, kidney function, clotting, and white blood cell count (confirm with trial site for exact values).
- People whose blood clotting results fall within acceptable ranges as measured by specific clotting tests.
- People who are able to understand the trial and are willing to sign a written consent form.
Who may not be able to join:
- People whose liver cancer is diffuse, meaning it is spread throughout the liver in a scattered pattern rather than in defined tumors.
- People whose cancer has spread to more than 5 sites outside the liver.
- People whose cancer has blocked the main portal vein (a major blood vessel supplying the liver).
- People who have serious other medical conditions alongside their cancer.
- People who show signs that their liver is failing, such as fluid build-up in the abdomen, gastrointestinal bleeding, or confusion caused by liver dysfunction.
- People with a known history of HIV.
- People who have previously had an organ transplant.
- People with a known or suspected allergy to any of the treatments or agents used in this trial.
- People who have irregular heart rhythms that require medication to control.
- People who have evidence of a bleeding disorder.
- People who have had a significant gastrointestinal bleed within the 30 days before joining the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhimei Hunag, MD, Sun Yat-sen University
Phone: 86 19868000115
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective response rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.